Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
David A. Palma(Western University), Suresh Senan(Amsterdam Neuroscience), Stewart Gaede(London Health Sciences Centre), George Rodrigues(London Health Sciences Centre), Jason Panarotto(Ottawa Regional Cancer Foundation), Michael Lock(London Health Sciences Centre), Brian Yaremko(London Health Sciences Centre), Ben J. Slotman(Vrije Universiteit Amsterdam), Max Dahele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Robert Olson(BC Cancer Agency), Cornelis J.A. Haasbeek(University of Amsterdam), GwendolynHMJ Griffioen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Mitchell Liu
Cited by 308
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k